# Semaglutide: What Durability Buys When Someone Runs the Trials > Semaglutide — Research Peptide Fundamentals Research Peptides — Peptide Coalition — A cited review of semaglutide (Ozempic, Wegovy, Rybelsus) within Research Peptide Fundamentals research peptides: how a reversible albumin tether made once-weekly dosing possible, and how once-weekly dosing made outcome trials possible. **03 / CROSS-CLASS REVIEW — THE SAME STRATEGY, CARRIED THROUGH** An acylated analogue of a gut hormone that survives two minutes in its native form. The engineering is close kin to CJC-1295's; the difference is a completed clinical programme enrolling more than seventeen thousand people. ## Abstract, in plain English Semaglutide (Ozempic, Wegovy, Rybelsus) is a rebuilt copy of GLP-1, a hormone the gut releases after a meal to signal fullness and help control blood sugar. The natural hormone lasts about two minutes. Semaglutide lasts about a week, and it gets there by two tricks: one amino acid is swapped so the enzyme that normally cuts the hormone in half no longer fits, and a long fatty chain is attached that grips albumin, the most abundant protein in blood, so the molecule is shielded from the kidneys. That is what makes a once-weekly injection possible, and the once-weekly format is what made very large trials practical. In a 68-week randomised trial, weekly semaglutide produced a mean weight change of about minus 15 per cent against minus 2 per cent for placebo [16]. In a trial of more than seventeen thousand people with heart disease, it reduced major cardiovascular events [15]. In a trial of more than three thousand people with diabetes and kidney disease, it reduced kidney events [14]. It is an approved prescription medicine. Its most common problems are digestive, and they cluster around dose increases [17]. ## Definition and provenance Semaglutide is a thirty-one-residue acylated analogue of human glucagon-like peptide-1, sharing roughly 94 per cent sequence homology with the native hormone. Three modifications define it. At position 8, alanine is replaced with alpha-aminoisobutyric acid, which blocks cleavage by dipeptidyl peptidase-4 — the same enzyme class CJC-1295's substitutions were designed to defeat. At position 34, lysine is replaced with arginine, leaving a single lysine at position 26. That remaining lysine is acylated with a C18 fatty di-acid chain attached through a glutamic-acid and OEG spacer. The fatty chain is the durability engine. It drives strong but reversible binding to serum albumin, which protects the peptide from renal clearance and from metabolism, and it is the structural basis for once-weekly dosing rather than the roughly two-minute survival of native GLP-1. The contrast with CJC-1295 is worth stating precisely, because the two molecules solved the same problem by neighbouring routes. CJC-1295 binds albumin **covalently**, through a maleimidopropionyl linker reacting with a free thiol [12]; semaglutide binds it **reversibly**, through a lipid that associates and dissociates. A covalent bond gives longer persistence; a reversible one gives a pharmacology that can be titrated and stopped. For a drug intended to be given to millions of outpatients, reversibility is the more useful property, and the difference in approach maps closely onto the difference in what became of each compound. ## Mechanism Semaglutide is a long-acting agonist at the glucagon-like peptide-1 receptor. Activating that receptor potentiates glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon release from alpha cells, and slows gastric emptying. Its weight-lowering effect, however, is primarily central rather than gastric. The molecule reaches appetite circuitry in the hypothalamus and brainstem — notably the arcuate nucleus and the area postrema — where it activates anorexigenic POMC and CART neurons and inhibits orexigenic NPY and AgRP neurons, reducing food intake and shifting food preference without lowering energy expenditure. The brainstem targets also explain the adverse-effect profile: the area postrema and parabrachial nucleus mediate meal termination and nausea alike, so the sensation people describe as appetite suppression and the sensation they describe as queasiness arise from overlapping circuitry. Additional GLP-1 receptors in cardiovascular and renal tissue are the presumed substrate for the pleiotropic protective effects seen in the outcome trials [14][15], though the mechanisms there remain incompletely resolved. ## The published record Semaglutide has the largest and most mature clinical file of any compound in this review, and it is the only one whose evidence includes hard clinical endpoints rather than biomarkers or patient-reported scales. In the STEP 1 randomised trial, once-weekly subcutaneous semaglutide at 2.4 mg produced a mean body-weight change of minus 14.9 per cent from baseline to week 68, against minus 2.4 per cent with placebo, in adults with overweight or obesity and without diabetes [16]. In the SELECT trial, 17,604 adults with pre-existing cardiovascular disease and overweight or obesity but without diabetes received once-weekly semaglutide 2.4 mg or placebo; major adverse cardiovascular events were reduced with a hazard ratio of 0.80 (95 per cent confidence interval 0.72 to 0.90, P less than 0.001) [15]. In the FLOW trial, 3,533 participants with type 2 diabetes and chronic kidney disease received once-weekly semaglutide 1.0 mg or placebo; major kidney-disease events — kidney failure, a fall in eGFR of 50 per cent or more, or death from kidney or cardiovascular causes — were reduced with a hazard ratio of 0.76 (95 per cent confidence interval 0.66 to 0.88) [14]. The head-to-head data place it in its class. In SURMOUNT-5, 751 adults with obesity were randomised to tirzepatide or semaglutide; tirzepatide produced greater mean weight loss at 72 weeks, minus 20.2 per cent against minus 13.7 per cent, a statistically significant difference (P less than 0.001) [13]. A dedicated safety review concludes the overall risk-benefit profile in type 2 diabetes is favourable, with mostly mild-to-moderate and transient gastrointestinal effects — nausea in roughly a third of patients — an increased risk of biliary disease, and pancreatic and thyroid-cancer signals for which definitive conclusions cannot yet be drawn because incidence is low [17]. ## Reported effects and documented cautions The reports summarised first here are anecdotal, not clinical evidence: they come from patient reviews and community discussion rather than from trial data, and no doses are attached to them. The most frequently described benefit is not weight loss but the quieting of what people call food noise — the constant background preoccupation with the next meal — often within the first week or two, alongside feeling full on much smaller portions. Cravings for sweet and for fried or greasy food are reported to drop sharply, sometimes to the point of aversion, with several people describing a spontaneous shift toward lighter meals. Weight loss itself is described as steady and substantial over months, with the pace slowing after the early period. People treating type 2 diabetes commonly report markedly better glucose and HbA1c readings. A recurring secondary observation is a reduced desire to drink alcohol. On the adverse side, nausea leads, mentioned by roughly a third of reviewers and escalating to vomiting in a subset; it tends to peak in the first weeks and after each dose increase. Sulfurous burps are a distinctive and frequently mentioned complaint, often arriving after a dose increase and accompanied by bloating. Bowel changes run to both extremes, sometimes alternating. Reflux and heartburn track dose increases. Fatigue in the first day or two after injection is common early on. Food aversions, taste changes, heightened sensitivity to smell, and occasionally over-suppressed appetite are reported. Hair shedding and facial gauntness appear a few months in and are widely attributed by reviewers themselves to the speed of weight loss rather than to the drug. The documented cautions are considerably firmer, because this compound has the trial base to support them. **Gastrointestinal intolerance during dose escalation** dominates the adverse-effect profile in trials and is the leading cause of discontinuation, predominantly mild-to-moderate and transient, with nausea affecting roughly a third of patients [17]. **A boxed warning covers medullary thyroid carcinoma and MEN-2**, derived from rodent C-cell tumours at supratherapeutic exposures; a personal or family history is a contraindication, and available human data have not established a clear increase in thyroid cancer. **Acute pancreatitis is a class warning**, and treatment is conventionally stopped if pancreatitis is suspected; pancreatic-cancer signals remain ones on which definitive conclusions cannot yet be drawn owing to low incidence [17]. **Biliary disease is increased**, attributed largely to the rate and magnitude of weight loss rather than direct toxicity [17]. **Pre-existing diabetic retinopathy** worsened more often in SUSTAIN-6, with a hazard ratio of 1.76 (95 per cent confidence interval 1.11 to 2.78), concentrated among patients undergoing rapid correction of HbA1c. **Lean-mass loss** is a documented component of the weight lost, raising a sarcopenia concern particularly in older adults. **Weight regain follows discontinuation**, with roughly 11.6 percentage points of body weight regained within a year in the STEP 1 extension and cardiometabolic improvements reverting toward baseline. **Pregnancy is a contraindication**, with a multi-week washout advised before planned conception because of the long half-life. **The oral formulation requires strict fasted administration**, since its SNAC-enabled bioavailability is only about 0.4 to 1 per cent and administration errors substantially reduce the absorbed dose. And **narrow-therapeutic-index oral drugs warrant monitoring during titration**, although a systematic review found delayed gastric emptying does not generally produce clinically significant interactions. ## Its position in the coalition Semaglutide is the case that completes the argument. Its durability engineering is not more sophisticated than CJC-1295's — arguably it is less so, since a reversible lipid tether is a gentler intervention than a covalent conjugation. What separates the two is everything that happened after the chemistry. A once-weekly injection is a format a sponsor can build a programme around. Seventeen thousand people can be randomised to it and followed for years [15]; three thousand can be followed to a kidney endpoint [14]; a 68-week weight trial is unremarkable rather than heroic [16]. None of those designs is available to a compound that must be injected daily or several times a day. The durability engineering did not merely make semaglutide convenient; it made the evidence base that now defines it operationally possible. The same property writes the adverse-effect calendar. Because exposure is sustained across a week and rises stepwise with each titration, the gastrointestinal effects cluster at dose increases and persist through them rather than passing in an afternoon [17]. Because the half-life is long, a pregnancy washout is measured in weeks. Compare PT-141, reviewed later, whose adverse effects arrive within an hour and resolve within hours [26][27] for exactly the same reason in reverse. And semaglutide marks the boundary of the thesis. Duration explains the shape of its file — the trial sizes, the endpoint types, the timing of its side effects. It explains nothing at all about *what* the drug does. That comes from the receptor, and the receptor is not shared with any other compound in this coalition. --- Peptide Coalition is an independent review desk that reads the peptide literature across classes for what recurs; it cites its sources, sells nothing, and prescribes nothing to anyone.